Tag: outperform rating
-
CRISPR Therapeutics Could be a Standout Winner this Year
Gene editing stocks, like CRISPR Therapeutics (CRSP), are on the. move. In fact, CRSP is up about 15% on the day on a volume spike to 2.6 million shares, as compared to daily average volume of 1.04 million. All after analysts at Cantor Fitzgerald initiated coverage with an outperform rating, with a $72 price target. …